Aflibercept

BNF:
Eye
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

RED

  • NICE TA294: injection for treating wet age-related macular degeneration.  (Decision date - August 2013)
  • NICE TA305: for visual impairment caused by macular oedema secondary to CRVO.  (Decision date - March 2014)
  • NICE TA346: for treating diabetic macular oedema.  (Decision date - August 2015)
  • NICE TA409: for visual impairment caused by macular oedema after branch retinal vein occlusion.  (Decision date - October 2016)
  • NICE TA486: for treating choroidal neovascularisation.  (Decision date - December 2017).

Do Not Prescribe (DNP)

  • NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy.  (Aflibercept can be funded through the cancer drug fund for this indication.  Seek advice from the oncologist/haematologist).  (Decision date - April 2014).

Black Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again